Pulmatrix (PULM)
(Delayed Data from NSDQ)
$2.19 USD
-0.01 (-0.45%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $2.13 -0.06 (-2.74%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
0 items in cart
Pulmatrix, Inc. [PULM]
Reports for Purchase
Showing records 1 - 20 ( 44 total )
Company: Pulmatrix, Inc.
Industry: Medical - Biomedical and Genetics
Company: Pulmatrix, Inc.
Industry: Medical - Biomedical and Genetics
PUR1900 in ABPA Leads iSPERSE Platform-Partnership Upside; Reit. Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Pulmatrix, Inc.
Industry: Medical - Biomedical and Genetics
Pipeline Progress Across ABPA and Acute Migraine, Cash Into 2025; Reit Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Pulmatrix, Inc.
Industry: Medical - Biomedical and Genetics
iSPERSE Program Advancement With PUR3100 IND Expected Mid-2023; Reit Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Pulmatrix, Inc.
Industry: Medical - Biomedical and Genetics
KOL Perspective in Acute Migraine-Broadening the Scope of iSPERSE
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Pulmatrix, Inc.
Industry: Medical - Biomedical and Genetics
iSPERSE Platform Progress with PUR3100 and PUR1800 Near-Term Catalysts
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Pulmatrix, Inc.
Industry: Medical - Biomedical and Genetics
Demonstrated Phase 1b Progress for PUR1800 Sets Tone for 2022; Reiterate Buy and Raising PT to $10, With Reverse-Split
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Pulmatrix, Inc.
Industry: Medical - Biomedical and Genetics
Pulmazole ABPA Program Advancement-Resolution of Cipla Dispute
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Pulmatrix, Inc.
Industry: Medical - Biomedical and Genetics
Company: Pulmatrix, Inc.
Industry: Medical - Biomedical and Genetics
Steady Progress Across Pipeline As Focus Stays on Top-Line Data for PUR1800 in 1Q22
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Pulmatrix, Inc.
Industry: Medical - Biomedical and Genetics
PUR1800 Top-line Data in 4Q21 Remains Primary Focus; Reit Buy and $5 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Pulmatrix, Inc.
Industry: Medical - Biomedical and Genetics
Despite Agreement Termination PUR1800 Development Advances; Data Expected 4Q21
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Pulmatrix, Inc.
Industry: Medical - Biomedical and Genetics
Looking to 2021 for Pipeline Advancement; PUR1800 Top-line Expected 4Q21
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Pulmatrix, Inc.
Industry: Medical - Biomedical and Genetics
iSPERSE Platform Advancement With PUR1800 Topline Expected 4Q21
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Pulmatrix, Inc.
Industry: Medical - Biomedical and Genetics
iSPERSE Platform Remains Resolute; 2021 Presents Decisive Year for Progress
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Pulmatrix, Inc.
Industry: Medical - Biomedical and Genetics
Amid Pandemic''s Impact on Revised Pipeline Strategy, the Band Plays on; Pulmazole FDA Clarity Expected 1Q21
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Pulmatrix, Inc.
Industry: Medical - Biomedical and Genetics
Sensory Cloud Strategic Partnership Moves Platform Forward, Phase 2 ABPA Trial Expected 2021
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Pulmatrix, Inc.
Industry: Medical - Biomedical and Genetics
Collaborations Expand iSPERSE Technology; Multiple Data Readouts in 2021; Reit Buy and $10 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Pulmatrix, Inc.
Industry: Medical - Biomedical and Genetics
Strategic Partnerships Further Define Ongoing Pulmazole and PUR1800 Advancement
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Pulmatrix, Inc.
Industry: Medical - Biomedical and Genetics
Recent Licensing Agreement and Research Collaboration Pave Way to Pulmazole Data Expected 4Q20; Reit Buy and $10 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A